Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis
- Cell Death Differ. 2020 Jun;27(6):1795-1806. doi: 10.1038/s41418-019-0459-6.
- 1. Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, 200241, Shanghai, China.
- 2. Department of Orthopedic Oncology, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, 200003, Shanghai, China.
- 3. Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, 646000, Sichuan, China.
- 4. Department of Pathology, the Second Chengdu Municipal Hospital, 610017, Chengdu, China.
- 5. State Key Laboratory of Proteomics, Genetic Laboratory of Development and Disease, Institute of Biotechnology, 100071, Beijing, China.
- 6. Department of Molecular and Cellular Biology, Dan L. Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
- 7. Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, 200241, Shanghai, China. [email protected].
- 8. Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, 200241, Shanghai, China. [email protected].
- # Contributed equally.
Lung Cancer is one of the cancers with highest morbidity and mortality rates and the metastasis of lung Cancer is a leading cause of death. Mechanisms of lung Cancer metastasis are yet to be fully understood. Herein, we demonstrate that mice deficient for REGγ, a Proteasome activator, exhibited a significant reduction in tumor size, numbers, and metastatic rate with prolonged survival in a conditional Kras/p53 mutant lung Cancer model. REGγ enhanced the TGFβ-Smad signaling pathway by ubiquitin-ATP-independent degradation of Smad7, an inhibitor of the TGFβ pathway. Activated TGFβ signaling in REGγ-positive lung Cancer cells led to diminished expression of E-cadherin, a biomarker of epithelial-mesenchymal transitions (EMT), and elevated mesenchymal markers compared with REGγ-deficient lung Cancer cells. REGγ overexpression was found in lung Cancer patients with metastasis, correlating with the reduction of E-Cadherin/Smad7 and a poor prognosis. Overall, our study indicates that REGγ promotes lung Cancer metastasis by activating TGF-β signaling via degradation of Smad7. Thus, REGγ may serve as a novel therapeutic target for lung cancers with poor prognosis.